Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karilyn Haut

Physician Assistant, Medical Arroyo Grande, CA Physician Assistant

NPI 1952634743 CMS profile 11226925

310 S Halcyon Rd Ste 106, Arroyo Grande, CA 93420

Open in the dashboard

General payments

$10,427

287 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karilyn Haut of Arroyo Grande, CA is reported in the CMS Open Payments database as having received $10,427 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $929 55
2024 General $1,648 81
2023 General $6,635 67
2022 General $635 45
2021 General $579 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karilyn Haut
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Karilyn Haut were reported at $929. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Karilyn Haut Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $579 $156 $41–$563 $132
2022 $635 $185 $55–$649 $149
2023 $6,635 $199 $58–$717 $160
2024 $1,648 $206 $62–$740 $164
2025 $929 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Acera Surgical, Inc. $5,421 2 payments
  2. AbbVie, Inc. $1,299 97 payments
  3. Janssen Biotech, Inc. $796 60 payments
  4. Lilly USA, LLC $494 16 payments
  5. UCB, Inc. $456 18 payments
  6. Regeneron Healthcare Solutions, Inc. $415 16 payments
  7. Genzyme Corporation $326 14 payments
  8. Galderma Laboratories, L.P. $235 6 payments
  9. LEO Pharma Inc. $221 19 payments
  10. Novartis Pharmaceuticals Corporation $164 5 payments
  11. Other $599 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Debt forgiveness $5,400 1 payment
  2. Food and Beverage $4,650 278 payments
  3. Education $261 4 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $117 4 payments
Products named General payments · program years 2021–2025
  1. Restrata Wound Matrix $5,421 2 payments
  2. SKYRIZI $743 62 payments
  3. TREMFYA $532 40 payments
  4. TALTZ $370 15 payments
  5. DUPIXENT $306 12 payments
  6. Cimzia $297 11 payments
  7. SIMPONI ARIA $264 20 payments
  8. STELARA $264 20 payments
  9. REMICADE $264 20 payments
  10. SIMPONI $264 20 payments
  11. Other $2,025 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

786

Median for Physician Assistant: 241

Drug cost

$119,570

Median for Physician Assistant: $4,110

Branded share of claims

8.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 22 $86,819
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 19 $12,036
Fluorouracil Generic 112 $7,922
Clobetasol Propionate Generic 109 $5,028
Ketoconazole Generic 75 $2,588
Minocycline Hcl Generic 82 $1,272
Mometasone Furoate Generic 68 $1,180
Triamcinolone Acetonide Generic 41 $723
Minoxidil Generic 43 $420
Clindamycin Phosphate Generic 12 $322

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$334,661

Of which drugs: $24,327

Medicare patients

1,153

Average age 73

Services billed

6,258

705 women, 448 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 42%
Osteoporosis 17%
Diabetes 16%
Depression 16%
Chronic kidney disease 15%
Ischemic heart disease 14%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 24 56 $17,370
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 52 156 $115

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $262
$262 — —
TREMFYA
  • Janssen Biotech, Inc. $227
$227 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $121
  • GENZYME CORPORATION $98
$219 22 —
TALTZ
  • Lilly USA, LLC $169
$169 — —
Bimzelx
  • UCB, Inc. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record